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ABSTRACT 
The metabolism of flavone-8-acetic acid (FAA) has been hypothesized to be partly 
responsible for its potent anticancer activity in mice. The purpose of this study was to identify 
the mouse enzymes involved in FAA Phase I metabolism and evaluate their possible 
induction in vivo by FAA. Mouse microsomes metabolized FAA into 6 metabolites: 3',4'-
dihydrodiol-FAA, 5,6-epoxy-FAA, 4'-OH-FAA, 3’-OH-FAA, 3’,4’-epoxy-FAA and 6-OH-
FAA. Using Cyp-specific inhibitors (furafylline, Cyp1a2; α-naphthoflavone, Cyp1b1; 
tranylcypromine, Cyp2b9; quercetin, Cyp2c29; quinidine, 2d9; diethyldithiocarbamate, 
Cyp2e1; ketoconazole, Cyp3a11), the formation of  5,6-epoxy-FAA was mainly attributed to 
Cyps 1a2, 1b1, 2b9, 2c29 and 2e1, whereas the 3’,4’-epoxy-FAA was formed by Cyps 2b9 
and 3a11. The 4’-OH-FAA was generated by Cyps 1a2, 1b1, 2b9 and 2e1, and the 6-OH-FAA 
was formed by Cyps 1b1 and 2c9. Using the epoxide scavenger N-acetyl cysteine, 4’-OH-
FAA, 3’-OH-FAA and 6-OH-FAA were shown to derive partly from non enzymatic 
isomerisation of their corresponding epoxides. The specific epoxide hydrolase inhibitor 
elaidamide allowed the confirmation that 3’,4’-dihydrodiol-FAA was formed via the epoxide 
hydrolase. FAA treatment in vivo in mice led to a significant increase in the hepatic 
expression of Cyp1a2 (1.9-fold), 2e1 (2.1-fold), 2b10 (3.2-fold), 2d9 (2.3-fold) and 3a11 (2.2-
fold), as evaluated by qRT-PCR. In conclusion, several Cyps were shown to be involved in 
FAA metabolism, particularly Cyps 3a11 and 2b9 which were responsible for the formation 
of the principal metabolites (5,6-epoxy-FAA, 3',4'-epoxy-FAA), and that FAA could induce 
the expression of several Cyps after in vivo administration. The possible implication of these 
enzymes in the in vivo anticancer activity of FAA in mice is discussed. 
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I!TRODUCTIO! 
The flavonoids are natural compounds possessing a large range of biochemical and 
pharmacological properties [1] including antitumoral activities [2]. Among the flavonoids 
identified as potential anticancer agents, flavone-8-acetic acid (FAA; 2-phenyl-8-
(carboxymethyl)benzopyran-4-one; NSC-347512; LM975; Figure 1-A) emerged as an 
interesting lead because of its potent anticancer activity in mouse solid tumors [3-6] and also 
in human tumors transplanted in nude mice [7;8]. However, despite its impressive antitumor 
activity reported in murine models, FAA has not shown anticancer activity in humans [9;10]. 
This marked interspecies difference in FAA anticancer activity has been hypothesized to be 
due to a possible metabolic activation of this flavonoid in vivo in mice [11;12]. 
 The mechanism of anticancer activity of FAA in mice is not fully elucidated. FAA is 
weakly cytotoxic in vitro but is active in vivo when the same cell lines are transplanted in 
mice [12-14]. In view of this discrepancy between in vivo and in vitro effectiveness, several 
indirect mechanisms of anticancer action have therefore been suggested: augmentation of 
natural killer activity and induction of interferon [15]; antiangiogenic properties [16]; tumor 
blood flow shut down and induction of extensive hemorrhagic necrosis [3;17-20]. At the 
molecular level, FAA has been reported to induce DNA damage in Glasgow osteogenic 
sarcoma after in vivo administration, which could hint to an in vivo formation of reactive 
metabolites in mice [21]. 
 In view of the poor cytotoxic activity of FAA in vitro and its potent anticancer activity 
in vivo in mice, the requirement for FAA metabolic activation has therefore been 
hypothesized [11;12]. In a search for potentially active FAA metabolites, we have previously 
identified six FAA phase I metabolites formed in vitro using mouse microsomes [22]. The 
identified metabolites include three monohydroxylated derivatives (3'-OH-FAA, 4'-OH-FAA 
and 6-OH-FAA), two epoxides (3',4'-epoxy-FAA and 5,6-epoxy-FAA), and one dihydrodiol 
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(3',4'-dihydodiol-FAA) (Figure 1-A) [22]. We have also shown that human microsomes were 
unable to metabolize this compound to a significant extent, as compared with mouse 
microsomes [22]. Although the mouse genome contains 72 putatively functional CYP genes 
compared to only 27 in humans [23], the cytochrome P450s (CYP) sub-families mostly 
involved in drug metabolism, i.e., the CYP1A, CYP2B, CYP2E, CYP3A and CYP4A appear 
to be roughly similar between mouse and man, although differences are observed in activity 
and also in inhibition studies [24;25]. 
Although mouse microsomes were shown to metabolize FAA, the enzymes 
responsible for their production are not presently identified. The purpose of the present study 
was therefore to identify the mouse enzymes involved in the formation of the principal FAA 
metabolites. The identification of the various mouse cytochrome P450s (Cyps, in lower case 
for mice) was accomplished using Cyp-specific inhibitors, and the implication of epoxide 
hydrolase was tested using elaidamide, a specific epoxide hydrolase inhibitor. In addition, 
because flavonoids have been shown to influence the expression of several Cyps after in vivo 
administration [26], the influence of FAA treatment in mice on the expression of the principal 
hepatic Cyps was also investigated using quantitative RT-PCR. We have found that different 
sets of Cyps are involved in the formation of specific FAA metabolites and that FAA was 
shown to induce several hepatic Cyps after in vivo administration in mice. 
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MATERIALS A!D METHODS 
Chemicals. Flavone-8-acetic acid (FAA, LM975, NSC347512, Fig. 1-A) and FAA 
mono-hydroxylated products at position 3' or 4' were kindly provided by Dr Jean-Jacques 
Berthelon (Merck-Lipha Santé, Lyon, France). The 6-OH-FAA was synthesized as previously 
described [22] using appropriate starting material [27-29]. The 3’,4’-dihydrodiol-FAA, the 
3’,4’-epoxy-FAA and the 5,6-epoxy-FAA were generated in vitro using aroclor 1254 induced 
mouse microsomes according to the protocol described below. The following Cyp inhibitors 
were purchased from Sigma-Aldrich: furafylline (Cyp1a2), α-naphthoflavone (Cyp1b1), 
tranylcypromine (Cyp2c29, Cyp2c39), quercetin (Cyp2c29), quinidine (Cyp2d9), 
diethyldithiocarbamate (Cyp2e1) and ketoconazole (Cyp3a11). The specific epoxide 
hydrolase inhibitor elaidamide was synthesized and kindly provided by Dr Christophe 
Morisseau [30]. Aroclor 1254 was obtained from Sigma-Aldrich (Saint Quentin Fallavier, 
France). All other chemicals were obtained from commercial suppliers and were of the 
highest purity available. 
Preparation of aroclorinduced mouse microsomes. Aroclor-induced mouse 
microsomes were prepared according to the protocol described by Breinholt et al. [31]. 
Female C57Bl/6 mice, 8 weeks of age were purchased from Janvier (Le Genest-St-Isle, 
France) and acclimated for a week in our animal facility and kept on a 12 h light/dark cycle 
with free access to food. Mice were injected intraperitoneally with aroclor-1254 (500 mg/kg 
body weight) dissolved in corn oil on day 0, and 5 days later the mice were sacrificed by 
cervical dislocation after a 24 h fasting period. All animal experiments complied with the 
French regulations concerning the protection of animals used for experimental and other 
scientific purposes (D2001-486), and with the European Commission regulations (OJ of 
ECL358 12/18/1986). The hepatic microsomes were prepared as described by Guengerich 
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[32]. Briefly, the livers were immediately excised and rinsed in ice-cold KCl 1.15 % solution, 
pooled and cut into small pieces with scissors. Four volumes of 0.1 M phosphate buffer (pH 
7.4) were added and the livers homogenized using a Teflon potter at a speed of 50 rpm with 
10 strokes. The liver homogenate was centrifuged at 15,000 × g for 20 min. After lipid 
elimination, the supernatant was ultra-centrifuged at 100,000 × g during 60 min, at 4°C. The 
pellet containing the microsomes were collected, covered by a phosphate buffer containing 
20% glycerol, snap frozen on dry ice, and stored at – 80°C until use. Total microsomal protein 
was determined using the Pierce BCA Protein Assay Reagent Kit (Rockford, IL,USA). 
In vitro metabolism of FAA. Metabolism of FAA was carried out according to our 
previously described protocol [22]. In brief, FAA (8 µg/ml final concentration) was incubated 
in 300 µl TRIS-HCL 0.1 M buffer, pH 7.4, containing 0.5 mg/ml microsomal protein, 1.6 
mg/ml BSA, 5 mM MgCl2 and a NADPH generating system corresponding to 1.3 mM. The 
incubation was carried out in opened 2 ml polypropylene tubes in a shaking water bath (150 
oscillations/min) at 37°C. The reaction mixture was pre-warmed at 37°C for 3 min before the 
NADPH generating system was added and the incubation time was extended for an additional 
60 min. The generation of metabolites was linear with time up to 2 h and protein 
concentration up to 2 mg/ml of microsomal protein, therefore the conditions used in the 
inhibition experiments (1 h and 0.5 mg/ml protein) were within the linear range. The 
incubation mixture was extracted twice with 800 µl ethyl acetate containing 2% acetic acid 
(v/v), the organic phase was evaporated under nitrogen and kept in dry form at -80°C, and 
then reconstituted with 300 µl of the HPLC mobile phase immediately prior HPLC analysis. 
One hundred µl of the reconstituted residue were injected onto the Shimadzu HPLC system. 
In these incubation conditions, mouse aroclor-induced microsomes could metabolize 4.3 ± 0.3 
% of the FAA.  
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Determination of mouse Cyp enzymes involved in the FAA metabolism in vitro. 
To determine mouse Cyps involved in the FAA metabolism, FAA metabolism by aroclor-
induced mouse microsomes in vitro was carried out in absence or presence of various 
concentrations of specific Cyp inhibitors. The mouse Cyp orthologs corresponding to their 
human CYP counterparts are as follows [23]: Cyp1a2, CYP1A2; Cyp1b1, CYP1B1; Cyp2b9, 
CYP2B6; Cyp2c39, CYP2C19; Cyp2d9, CYP2D6; Cyp2e1, CYP2E1; Cyp3a11, CYP3A4. 
The specific Cyp inhibitors used were: furafylline (Cyp1a2), α-naphthoflavone (Cyp1b1) 
[33], tranylcypromine (Cyp2c29), quinidine (Cyp2d9) [34], diethyldithiocarbamate (Cyp2e) 
[35] and ketoconazole (Cyp3a11) [36]. Furafylline, α-naphthoflavone and ketoconazole were  
dissolved in DMSO, quercetin was dissolved in methanol, and tranylcypromine, quinidine, 
and diethyldithiocarbamate were dissolved in Tris-HCl buffer. Appropriate controls were run 
for the solvents which did not exceed 2% in volume in the control tube and in the test tube. 
The choice of inhibitors range concentrations were based on Bogaards et al. [24] (and 
references therein). The inhibitors were added to the incubation mixture containing 
microsomes 10 min before the addition of the NADPH generating system. The incubation and 
extraction conditions were carried out as described above for aroclor-induced mouse 
microsomes. 
Epoxide hydrolase inhibition. Because the 3’,4’-dihydrodiol-FAA was likely 
generated from the hydolysis of the 3’,4’-epoxy-FAA by the epoxide hydrolase, we 
determined the role of this enzyme using elaidamide, an epoxide hydrolase inhibitor [30], at 
final concentrations of 2, 4 and 10 µM. 
!onenzymatic transformations. Non-enzymatic transformations during FAA 
metabolism incubation were determined by analysis of transformation of FAA metabolites in 
PBS buffer. FAA metabolites extract was reconstituted in 300 µl PBS buffer incubated at 
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37°C in a shaking water bath and injected onto the Shimadzu HPLC system at time 0 and 60 
min. 
Evaluation of direct or indirect hydroxylation. In order to determine if FAA 
monohydroxylates were formed directly from FAA or indirect via epoxidation (Guengerich et 
al., 2003), FAA metabolism by aroclor-1254 induced mouse microsomes was carried out in 
presence of the epoxide scanvenger N-acetyl cysteine (NAC) according to the protocol 
described by Bu et al. [37]. In brief, NAC was added to the the pre-warmed incubation 
mixture at a final concentration of 7.5 mM. FAA metabolites and NAC adducts were further 
analyzed on the LC/MS systems described below. 
HPLCUV and HPLCUVMS conditions. Two HPLC systems were used during 
this project. The first, HPLC-UV system was a Shimadzu CLASS-VP
®
 (version 5.3), 
equipped with a C18 column (Beckman Ultrasphere ODS, 5 µm; 4.6 × 25 mm) thermostated at 
20°C, and a UV detector set at 300 nm. The mobile phase consisted of a solution of 26% 
methanol, 19% acetonitrile, 55% aqueous acetic acid (2%), at a flow rate of 1 ml/min. The 
second system of LC-MS/MS consisted of a Surveyor

 HPLC equipped with a UV diode 
array detector and was coupled with a mass spectrometer (LCQ-Advantage

, 
ThermoElectron). The mass spectrometer consisted of an electrospray ionization system used 
in positive ion polarity mode and a quadrupole ion trap mass analyzer. The operating 
parameters where as follows: the spray needle voltage was set at 4.0 kV and the spray was 
desolvated with a nitrogen sheath gas. Electrospray capillary voltage was 4.0 V, nitrogen was 
used as auxilliary gas and the capillary temperature was 250°C. A C18 reversed phase column 
(EC. 250/2 Nucleodur Sphinx RP, 5 µm, 250 mm X 2.1 mm, Macherey-Nagel) thermostated 
at 30°C was used. The metabolites were resolved using the following tertiary gradient: from 0 
to 25 min: 7-24% methanol; 4-13 % acetonitrile; 89-63 % TFA 0.1 %. From 25 to 40 min: 24-
26 % methanol; 13-14 % acetonitrile; 63-60 % TFA 0.1 %. From 40 to 42 min: 26-45 % 
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methanol; 14-22 % acetonitrile; 60-33 % TFA 0.1 %. From 42 to 47 min: 45 % methanol; 22 
% acetonitrile; 33 % TFA 0.1 %. From 47 to 49 min: 45-7 % methanol; 22-4 % acetonitrile; 
33-89 % TFA 0.1 %. And, finally from 49 to 75 min: 7 % methanol; 4 % acetonitrile; 89 % 
TFA 0.1 %. Flow rate was 0.2 ml/min. Volume of injection was 50 µl. The Xcalibur
®
 
software was used for data acquisition and analysis. 
In vivo treatment with standard Cyp inducers and FAA. Female C57Bl/6 mice, 8 
weeks of age were purchased from Janvier (Le Genest-St-Isle, France) and acclimated for a 
week in our animal facility and kept on a 12 h light/dark cycle with free access to food. The 
mice were injected i.p. (intraperitoneally) in a volume of 0.2 ml with the following inducers at 
the indicated doses and schedules (five mice per group): Control A mice received 0.9% saline 
i.p. for 3 consecutive days; Control B mice received corn oil i.p. on 3 consecutive days; 3-
Methylcholanthrene, 80 mg/kg, i.p., suspended in corn oil was administered for 3 consecutive 
days (Monday, Tuesday, Wednesday) [38], β-naphthoflavone, 80 mg/kg/day, i.p., suspended 
in corn oil, for 3 consecutive days [39]; Dexamethasone, 100 mg/kg/day, i.p., suspended in 
corn oil, for 3 consecutive days [39]; for all the previous treatments, the mice were sacrificed 
on the fifth day after an overnight fasting. Aroclor 1254 (500 mg/kg, dissolved in corn oil) 
was administered on day 1, and the mice were sacrificed on the 5th day after an overnight 
fasting [31]. Phenobarbital was administered in drinking water (0.1 %) for 10 days, and the 
mice were sacrificed on the 11th day after an overnight fasting. For FAA, two treatment 
schedules were tested: FAA treatment A, consisted of one i.p. one dose on day 1 (180 mg/kg), 
and the mice were sacrificed on day 5 after an overnight fasting [3;4] FAA treatment B 
included 3 i.p. administration (at 180 mg/kg each) on days 1, 3 and day 5, and the mice were 
sacrificed on day 9 after an overnight fasting [3;4]. Immediately upon sacrificing the mice 
(CO2), the liver was quickly removed, rinsed with ice cold PBS, and aliquots of each liver 
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lobe were immediately transferred to a tube containing a RNAlater solution (QIAGEN) and 
were kept at 4°C for further extraction of total RNA.  
Quantitative RTPCR. Extraction of total RNA was accomplished using RNable 
(Eurobio), and one microgram of total RNA, as measured with Ribogreen measurement, was 
reverse transcribed in a final volume of 20 µl containing 4 µL of 5 X RT buffer, 20 units of 
RNasin RNase inhibitor (Promega), 10 mM DDT, 100 units of Superscript II RNase H- 
reverse transcriptase (Invitrogen), and 3 mM random hexamers (Invitrogen). The samples 
were incubated at 20°C for 10 min, 42 °C for 30 min, and 99 °C for 5 min. Real-time PCR 
reactions were carried out using ABI PRISM 7900HT Sequence
 
Detection System (Applied 
Biosystems) in a 384-well,
 
clear optical reaction plate with optical adhesive covers (Applied
 
Biosystems). The PCR primers for the genes of interest were designed with the Oligo6 
software using the GenBank reference sequences (Table 1). They were chosen in such a 
manner to be in distinct exons, to ensure a specific cDNA versus genomic DNA 
amplification, and their specificity was assessed using the NCBI BLAST website. Reactions 
were run in a 5 µl volume in duplicate, with 2 µL of cDNA solution, 2.5 µL of Power SYBR 
Green Master Mix
 
(Applied Biosystems) and 0.5µL of 10 µM primers solution.
 
The PCR 
program was: 95°C for 10 min, followed by 45 cycles of (15 seconds at 95°C; 1 min at 60°C). 
Cycle threshold
 
values were obtained from the ABI PRISM 7900 SDS software. For each 
PCR well, raw fluorescence data were exported and a curve-fitting method was applied to 
evaluate the individual efficiencies [40]. For each target the efficiency was considered as 
shared for all wells. This efficiency was set as the mean of the fitted individual efficiencies. 
Individual Ct values exported from the SDS software were used to calculate the relative 
expression level of target t in sample S:
s
tsCt
t

eff
),(
st,L
−
= , Ns being the normalization factor for 
sample S, here corresponding to the total cDNA level as measured with Oligreen. Oligreen 
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fluorescence measurements were carried out using the ABI PRISM 7900HT Sequence
 
Detection System. Reactions were run in a 10 µl volume in triplicate, with 5µL of cDNA 
solution and 5 µL of Oligreen stock solution (Invitrogen) 200x diluted in TE buffer. 
Fluorescence was continuously read at 80°C for 30 sec, a condition which ensures exclusive 
cDNA measurement [41].  
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RESULTS 
FAA metabolism using aroclorinduced mouse microsomes. Figure 1-A presents 
the structures of FAA metabolites formed by aroclor-induced mouse microsomes, and Figure 
1-B depicts a typical HPLC-UV chromatogram of FAA and its major phase I metabolites. The 
parent compound FAA eluted at 17.1 min, whereas the six previously identified metabolites 
[22], that were all more hydrophilic than FAA, eluted at the following retention times in this 
reversed-phase HPLC system (Figure 1-B): 3',4'-dihydrodiol-FAA (Rt 4.1 min); 5,6-epoxy-
FAA (Rt 7.6 min); 4'-OH-FAA (Rt 9.0 min); 3’-OH-FAA (Rt 10.0 min); 3’,4’-epoxy-FAA 
(Rt 11.2 min); and 6-OH-FAA (Rt 12.3 min). Among these metabolites, the two FAA 
epoxides (5,6-epoxy-FAA and 3’,4’-epoxy-FAA) were the predominant ones, representing 
36.3 ± 1.1 % and 26.7 ± 1.5 % of the total metabolite area, respectively (as evaluated at 300 
nm). The 3',4'-dihydrodiol-FAA, the 4'-OH-FAA, the 3'-OH-FAA and the 6-OH-FAA, 
represented 14.0 ± 0.6 %, 6.8 ± 0.6 %, 1.6 ± 0.6 % and 14.5 ± 1.0 % (n = 3) of the total 
metabolite area, respectively. 
 Mouse Cyp enzymes involved in FAA metabolism. In order to identify the mouse 
Cyps involved in FAA metabolism, incubations were carried out in absence or presence of 
increasing concentrations of the Cyp-specific inhibitors presented in Table 2. The possible 
interference between FAA metabolites and inhibitors (or their possible metabolites) was also 
assessed by incubating the inhibitors alone with mouse microsomes.  
 Furafylline, a Cyp1a2 inhibitor, was tested in the concentration range of 5, 10, 20 and 
50 µM. In absence of furafylline, all the above identified FAA metabolites were detected (Fig. 
2-A). In presence of furafylline (Rt, 5.2 min), which did not interfere with the elution profile 
of FAA metabolites (Fig. 2-B), all the FAA metabolites were reduced up to maximal values 
of 36 to 57% at the maximal inhibitor concentration used (50 µM) (Table 2). However, 
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because high inhibitor concentrations may lead to unspecific inhibition, the intermediate 10 
µM concentration appears as a better indicator of specific inhibition (above 20%) for the 
formation of metabolites 5,6-epoxy-FAA and 4’-OH-FAA. 
 The Cyp1b1 inhibitor α-naphthoflavone was tested at final concentrations ranging 
from 5 to 20 µM (Table 2). Most FAA metabolites were highly inhibited in presence of α-
naphthoflavone and the reduction of metabolite areas was also inhibitor concentration-
dependent with values of 70 to 89% at the maximal concentration of inhibitor (20 µM). Of 
interest, concerning the 3’,4'-epoxy-FAA, a biphasic effect was observed, as the low 
concentrations of the inhibitor (5 and 10 µM) led to an increase in the production of 3’,4'-
epoxy-FAA, whereas higher concentrations produced a maximum inhibition of 40% (Table 
2). As indicated above, because high concentrations of inhibitor may be involved in 
unspecific inhibition, it appears that at the intermediate concentration of 10 µM, the following 
metabolites were inhibited by more than 20%: 3',4'-dihydrodiol-FAA; 5,6-epoxy-FAA; 4'-
OH-FAA; and 6-OH-FAA. 
 The involvement of Cyp2b9 and Cyp2c39 was determined using the inhibitor 
tranylcypromine. All the metabolites achieved more that 40% inhibition at the the 
intermediate 50 µM concentration of the inhibitor, with the exception of the 6-OH-FAA 
(Table 2). 
 Quercetin, a Cyp2c29 inhibitor, led to a 52% inhibition of the 3',4'-dihydrodiol-FAA, a 
73% inhibition of the 5,6-epoxy-FAA and a 85% inhibition of the 6-OH-FAA at the highest 
concentration tested of 30 µM (Table 2). At the intermediate concentration of 20 µM, only 
5,6-epoxy-FAA and 6-OH-FAA were mostly inhibited with 48% and 53% inhibition, 
respectively. The chromatographic interference of quercetin with the elution of 4'-OH-FAA 
and 3', 4’-epoxy-FAA in our HPLC conditions precluded the detection of these metabolites 
with this inhibitor. However, the indirect production of these metabolites via the measurable 
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production of the 3',4'-dihydrodiol-FAA, probably generated via the 3',4'-epoxy-FAA, is an 
indirect evidence of an inhibition of these B ring metabolites. 
 The involvement of Cyp2d9 was determined using quinidine as the inhibitor. Our 
results demonstrated that Cyp2d9 was not significantly involved in the formation of any 
metabolite even at a relatively high inhibitor concentration of 10 µM which is twice the usual 
concentration employed for this inhibitor [24] (Table 2). 
 In presence of diethyldithiocarbamate, a Cyp2e1 inhibitor, the production of 5,6-
epoxy-FAA and 4’-OH-FAA was significantly inhibited (>20%) at an intermediate 
concentration of this inhibitor (100 µM) (Table 2). 
 The contribution of Cyp3a11 to the production of FAA metabolites was determined 
with the specific inhibitor ketoconazole at final concentrations ranging from 2 to 40 µM. In 
presence of low (2 µM) to moderate (4 µM) concentrations of this inhibitor, only the 3',4',-
dihydiol-FAA was highly inhibited by 75% and 88%, respectively, indicating that Cyp3a11 
was indeed involved in the formation of the 3’,4,-epoxy-FAA intermediate metabolite (Table 
2).  
Determination of direct or indirect monohydroxylation of FAA. Because the 
monohydroxylated FAA metabolites could be derived from 2 metabolic routes, i.e., a direct 
hydroxylation or an hydroxylation via an epoxidic intermediate [42], we next evaluated the 
contribution of each pathway to their formation. The metabolism of FAA was conducted in 
absence or presence of the epoxide scavenger N-acetylcysteine (NAC). Because NAC adducts 
are very hydrophilic, we had to use gradient elution conditions in order to separate the adducts 
from the other metabolites as described in Materials and Methods. 
 In absence of NAC, FAA was metabolized by aroclor-induced mouse microsomes into 
several metabolites as shown in Figure 3-A. In these highly resolutive gradient elution 
conditions, FAA metabolites were eluted at the following retention times (Rt): 3’,4’-
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dihydrodiol-FAA = 28.5 min; 5,6-epoxy-FAA = 39.7 min; 4’-OH-FAA = 43.9 min; 3’-OH-
FAA = 45.6 min; 3’,4’-epoxy-FAA = 47.4 min; 6-OH-FAA = 49.1 min; and, FAA = 56.6 min 
(Figure 3-A).  
In presence of the scavenger NAC, all metabolite peaks were reduced (Figure 3-B). 
However, the 2 epoxides and the 3’,4’-dihydrodiol-FAA peaks were more dramatically 
reduced compared to the other peaks (Figure 3-B). In parallel to the decrease of two epoxides, 
we also observed the formation of 4 new peaks at Rt of 26.4, 29.7, 30.2 and 31.5 min (Figure 
3-B). Mass spectrum analysis of these 4 new peaks presented the same molecular ion m/z 460 
[M+H]
+
 which corresponded to the molecular ion of conjugation of one FAA epoxide (MW 
296) with a molecule of NAC (MW 163) (Figure 3-C). 
 To ascertain that the NAC adducts were produced directly with the two FAA epoxides, 
and not from FAA or its monohydroxylated metabolites, we performed control incubations of 
FAA with microsomes, but without NAC (Figure 3-D) which did not show any peak at m/z 
460 [M+H]
+
. In addition, control incubations with FAA and its monohydroxylated derivatives 
(i.e., 3'-, 4'-, and 6-OH-FAA) with NAC, but without microsomes, did not yield any molecular 
ion at m/z 460 (results not shown), indicating that epoxide formation is required for the 
appearance of m/z peaks at 460. Because the presence of NAC was also accompanied by a 
complete disappearance of 3’,4’-dihydrodiol-FAA, it was therefore deduced that the latter was 
derived from its corresponding 3’,4’-epoxy-FAA. 
 As mentioned above, it was observed that in presence of NAC, the 4’-OH-FAA, the 
3’-OH-FAA and the 6-OH-FAA, were significantly reduced. The 4'-OH-FAA and the 3'-OH-
FAA peaks were reduced by 86 and 67%, respectively, whereas the 6-OH-FAA metabolite 
was diminished by 40% (Figure 3-B). However, because these peaks were not completely 
suppressed in presence of the scavenger NAC, this is an indication that direct oxidation of 
FAA to the monohydroxylated metabolites is also taking place. 
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!onenzymatic transformation of the epoxides to their corresponding 
monohydroxylated FAA derivatives. Because the two FAA epoxides were found unstable 
and that they apparently were transformed into their corresponding mono-hydroxylated 
derivatives in the incubation conditions (pH 7.4, 37°C), we next explored the possible 
contribution of their non-enzymatic transformations to their corresponding phenolic 
compounds. To do so, FAA metabolite extracts were reconstituted in PBS buffer and 
incubated at 37°C for 1h. We observed that the peak areas of the 5,6-epoxy-FAA decreased 
by 47%, whereas the 3',4'-epoxy-FAA decreased by 15%. In parallel, their corresponding 
phenols, i.e., the 6-OH-FAA peak was doubled (100 % increase), the 4’-OH-FAA was 
increased by 70%, and the 3’-OH-FAA was increased by 171%.  It is of interest that the 
formation of the 5-OH-FAA was not observed in this experiment. It was also noteworthy that 
the 3’,4’-dihydrodiol-FAA peak area was not altered significantly, indicating that this 
dihydrodiol is not generated by simple chemical hydrolysis of the corresponding parent 
epoxide, but could be derived from an enzymatic hydrolysis. 
 Involvement of microsomal mouse epoxide hydrolase in the formation of 3’,4’
dihydrodiolFAA. To study the possible involvement of mouse epoxide hydrolase in the 
formation of the 3’,4’-dihydrodiol-FAA, we used elaidamide, a specific epoxide hydrolase 
inhibitor. In absence of elaidamide, all the FAA metabolites were formed, as presented in 
Figure 4-A. The first metabolite peak at Rt of 4.1 min was the 3',4'-dihydrodiol-FAA. In 
presence of elaidamide (2 to 10 µM), the 3',4'-dihydrodiol-FAA peak was reduced 
significantly (Figure 4-B) and the decrease was found to be concentration dependent of the 
epoxide hydrolase inhibitor as shown in Figure 4-C. 
 Effect of FAA treatment on the expression of the principal Cyp enzymes in mice. 
Because some flavonoids have been reported to modulate the expression of several enzymes, 
we next explored the effects of an in vivo treatment of FAA in mice on the expression of the 
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principal hepatic Cyps using quantitative RT-PCR. For comparison purposes, the following 
standard inducers were also included in these experiments: phenobarbital, β-naphthoflavone, 
3-methylcholanthrene, dexamethasone and aroclor 1254. The results are presented in Table 3 
along with those of FAA after one or three in vivo treatments. 
 As expected, phenobarbital significantly induced the expression of Cyps 2b10, 2d9 
and 3a11, by a factor of 3.2-, 2.5- and 1.6-fold, respectively (Table 3). Also as expected, β-
naphthoflavone, 3-methylcholanthrene and aroclor were all potent inducers of several Cyps of 
the family 1 (Cyp1a1, 1a2, 1b1) (Table 3). Dexamethasone could also induce the following 
Cyps: Cyp1a1 (24-fold), 1a2 (4-fold), 1b1 (3.1-fold), 2b10 (1.7-fold), 2d9 (18-fold) and 3a11 
(3.6-fold). 
 Concerning the FAA, one treatment (180 mg/kg i.p.) unexpectedly led to a marked 
reduction of Cyp 1a1, 1a2 and 1b1 transcripts (Table 3). However, after 3 FAA treatments, 
the following Cyps were significantly induced: Cyp1a2 (1.9-fold), 2e1 (2.1-fold), 2b10 (3.2-
fold), 2d9 (2.3-fold), 3a11 (2.2-fold) (Table 3). 
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DISCUSSIO! 
 Although the metabolism of FAA has been hypothesized to be involved in its 
mechanism of anticancer activity in mice [11;12], the enzymes involved in FAA metabolism 
are presently unknown. The purpose of the present work was therefore to identify the 
principal phase I enzymes involved in FAA metabolism in vitro. In addition, because several 
flavonoids have been reported to be involved in the modulation of the expression of CYP 
enzymes [26], we were also interested to evaluate the possible effect of FAA treatment on the 
expression of the main Cyps expressed in mouse liver. 
 The principal FAA metabolites formed in vitro using aroclor-induced mouse 
microsomes consisted of one dihydrodiol (3',4'-dihydrodiol-FAA), three monohydroxylated 
metabolites (3’-OH-FAA, 4'-OH-FAA, 6-OH-FAA), and two epoxides (5,6-epoxy-FAA, 
3’,4’-epoxy-FAA). Of these metabolites, the two epoxides 5,6-epoxy-FAA and 3',4'-epoxy-
FAA were the predominant ones representing 36% and 27% of the total metabolites area, 
respectively. 
 Using Cyp-specific inhibitors, we have shown that the production of several FAA 
metabolites could be significantly reduced, thus providing novel information concerning the 
Cyp families and sub-families that are mostly involved in the formation of these metabolites. 
A summary of the principal mouse Cyps involved in FAA metabolism is presented in Figure 
5. It can be noted that for the cycle A oxidation, 5,6-epoxidation was best afforded by Cyps 
1a2, 1b1, 2b9, 2c39, 2c29, and 2e1, whereas for the 6-hydroxylation, Cyps 1b1 and 2c29 were 
the most effective. For cycle B epoxidation (3’,4’-epoxy-FAA), Cyp 2b9/2c39 and 3a11 were 
the principal Cyps involved. For the formation of 4'-OH-FAA, Cyps 1a2, 1b1, 2b9 and 2e1 
were the most effective. 
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 Because monohydroxylation of phenols can also be generated through epoxide 
intermediates [42;43], we also evaluated the indirect production of the three 
monohydroxylated metabolites via an intermediate epoxide using N-acetyl cysteine as an 
epoxide scavenger. In presence of NAC, the 4’-OH-FAA, the 3’-OH-FAA and the 6-OH-
FAA, were significantly reduced, indicating that a significant percentage of these 
hydroxylated metabolites were indeed derived from the non enzymatic isomerization of their 
corresponding epoxides. The involvement of epoxide hydrolase in the formation of the 3’,4’-
dihydrodiol-FAA was also confirmed using elaidamide, a specific inhibitor of this enzyme 
[30]. 
 We were next interested to assess the influence of FAA on the expression of the 
principal hepatic Cyps after an in vivo administration in the mouse, because the expression of 
these enzymes can indeed be influenced by flavonoids [26]. Using quantitative RT-PCR, FAA 
was surprisingly found to have a dual effect, i.e., the repression of some Cyps after only one 
treatment, and the induction of other Cyps after three treatments. Concerning the repression of 
the expression of Cyps of the 1a subfamily after one in vivo treatment, this rather unexpected 
result may be due to the fact that some flavonoids may act as ligand of the aryl hydrocarbon 
receptor (AhR) at low concentrations and repress the transcription of the Cyp1a gene [44-46]. 
For the Cyp1b subfamily no evident mechanism is presently available to explain its 
repression. 
 The induction of Cyps 1a2, 2e1, 2b10, 2d9 and 3a11 after three in vivo FAA 
treatments was also interesting. High concentrations of flavonoids have been previously 
shown to function as AhR agonists and may therefore activate the transcription of the Cyp1a 
gene. Since FAA is an unsubstituted flavonoid, it is remarkable that similar unsubstituted 
flavonoids, e.g., flavone and alpha-naphthoflavone, were also found to induce CYPs 1A1, 
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1A2 and 2B1/2 [44;47]. For the other Cyp subfamilies (i.e., 2d, 2e and 3a), there is no 
published data that we are aware of, concerning the induction of these Cyps by flavonoids. 
 In conclusion, we have found that several mouse Cyps are involved in the formation of 
FAA phase I metabolites. The two main metabolites formed in vitro were the 5,6-epoxy-FAA 
and the 3',4'-epoxy-FAA which were mainly formed by Cyps 1a2, 1b1, 2b9, 2c39, 2c29, and 
2e1, for the former, and Cyps 2b9, 2c39, 3a11 for the latter. The formation of 3'-OH-FAA and 
4'-OH-FAA were mainly derived from the 3',4'-epoxy-FAA, whereas 6-OH-FAA was mainly 
formed directly (60%) by Cyps 1b1 and 2c29. After an in vivo administration of FAA in 
mice, the expression of Cyps 1a1, 1a2 and 1b1 were repressed after one treatment, whereas 
three treatments led to an induction of Cyps 1a2, 2e1, 2b10, 2d9 and 3a11. 
 The enzymes identified in FAA metabolism, as well as their in vivo induction could 
probably play a role in the remarkable anticancer activity of FAA observed in mice. Although 
only phase I enzymes were studied in the present work, the involvement of other enzymes, 
particularly phase II enzymes, could also play a role in FAA anticancer activity because some 
flavonoids have recently been reported to exert their antiproliferative activity through sulfate 
conjugation [48]. 
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Table 1. Primers used for the determination of mouse cytochrome P450s (Cyp) mR!A 
 
Cyp gene Forward primer Reverse primer 
PCR product 
(bp) 
GenBank 
number 
Cyp1a1 867-GGGAGGTTACTGGCTCTGGA 1077-TGGACATTGGCATTCTCGT 220 NM_009992 
Cyp1a2 961-CCCGAGGAGAAGATTGTCAAC 1102-CGATCCCTGCCAACCAC 158 NM_009993 
Cyp1b1 1315-TGCCTGCCACTATTACGGA 1440-GTCCCTCCCCACAACCTG 143 NM_009994 
Cyp2b10 937-GGCTTCCTGCTCATGCTC 1020-CGGTCATCAAGGGTTGGT 101 NM_009999 
Cyp2d9 1173-CGCTTTGGGGACATTGTT 1257-GTTGGGGAGGAGGATCGT 102 NM_010006 
Cyp2e1 786-CACTGGACATCAACTGCCC 947-ATGAGAATCAGGAGCCCATA 181 NM_021282 
Cyp3a11 328-GTCACAGACCCAGAGACGAT 553-TTTGCCTTCTGCCTCAAGTA 245 NM_007818 
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Table 2. Determination of mouse cytochrome P450s (Cyps) involved in the metabolism 
of FAA  using Cyp specific inhibitors 
a
 
Percent inhibition 
Inhibitor 
(Cyp inhibited) 
Inhibitor 
Conc. 
(µM) 
3’,4’-di-
hydrodiol-
FAA 
5,6-epoxy-
FAA 
4’-OH-FAA 
3’, 4’-epoxy 
-FAA 
6-OH-FAA 
5 - 3 ± 5 b 19 ± 3 7 ± 4 - 2 ± 5 - 3 ± 8 
10 6 ± 6 34 ± 13 29 ± 10 5 ± 8 19 ± 12 
20 14 ± 8 42 ± 6 35 ± 3 27 ± 5 28 ± 5 
Furafylline  
(Cyp1a2) 
50 36 ± 1 57 ± 2 52 ± 3 54 ± 3 52 ± 6 
5 10 ± 1 5 ± 5 5 ± 4 - 29 ± 6 16 ± 1 
10 50 ± 1 21 ± 9 32 ± 20 - 18 ± 11 53 ± 1 
15 76 ± 2 42 ± 4 62 ± 15 11 ± 2 73 ± 1 
αnaphthoflavone 
(Cyp1b1) 
20 89 ± 3 76 ± 14 70 ± 15 40 ± 16 84 ± 4 
25 4 ± 10 23 ± 3 13 ± 4 10 ± 1 - 17 ± 31 
50 45 ± 8 52 ± 2 44 ± 5 42 ± 4 10 ± 34 
75 68 ± 1 68 ± 2 57 ± 2 59 ± 2 29 ± 33 
Tranylcypromine 
(Cyp2b9, Cyp2c39) 
100 75 ± 3 74 ± 3 64 ± 7 64 ± 3 37 ± 32 
10 - 21 ± 7 26 ± 6 NDc ND 25 ± 12 
20 13 ± 7 48 ± 11 ND ND 53 ± 8 
25 35 ± 11 62 ± 11 ND ND 76 ± 4 
Quercetin 
(Cyp2c29) 
30 52 ± 7 73 ± 6 ND ND 85 ± 4 
10 1 ± 4 17 ± 13 - 7 ± 13 - 5 ± 9 - 23 ± 11 
50 7 ± 4 20 ± 4 5 ± 4 - 7 ± 1 - 26 ± 3 
100 15 ± 8 27 ± 1 13 ± 7 - 16 ± 5 - 17 ± 3 
Quinidine 
(Cyp2d9) 
200 39 ± 2 35 ± 5 24 ± 5 - 13 ± 0 5 ± 10 
50 - 61 ± 12 1 ± 5 17 ± 7 - 66 ± 26 - 3 ± 4 
100 - 53 ± 8 24 ± 5 31 ± 7 - 67 ± 16 4 ± 10 
200 - 29 ± 20 49 ± 6 54 ± 2 - 62 ± 46 34 ± 5 
Diethyldithiocarbamate 
(Cyp2e1) 
300 28 ± 15 75 ± 4 71 ± 9 11 ± 17 62 ± 2 
2 75 ± 3 17 ± 8 - 40 ± 6 - 82 ± 7 - 16 ± 2 
4 88 ± 1 16 ± 1 - 20 ± 20 - 101 ± 10 - 9 ± 11 
10 94 ± 1 41 ± 5 - 32 ± 31 - 62 ± 9 2 ± 13 
20 96 ± 1 61 ± 4 25 ± 6 0 ± 7 35 ± 7 
Ketoconazole 
(Cyp3a11) 
40 97 ± 1 85 ± 1 62 ± 11 59 ± 2 78 ± 1 
a
  Microsomal incubation were carried out as described in Materials and Methods section in absence or 
presence of the indicated inhibitor concentrations. The 3'-OH-FAA is not shown because it represented 
only about 2% of total metabolites. The mouse Cyp orthologs correspondance with the human CYPs 
are as follows (mouse Cyp, human CYP): Cyp1a2, CYP1A2; Cyp1b1, CYP1B1; Cyp2b9, CYP2B6; 
Cyp2c39, CYP2C19; Cyp2d9, CYP2D6; Cyp2e1, CYP2E1; Cyp3a11, CYP3A4. 
b
 Mean ± SEM of 3 independent determination. 
c 
ND, not determined, because of inhibitor peak 
interference with these metabolites. Bold characters indicate intermediate inhibitor concentrations. 
 
27 
Table 3. Quantitative RTPCR determination of the principal cytochrome P450s (Cyp) 
induced by standard inducers and flavone8acetic acid (FAA) 
a
 
Inducer 1a1
b 
1a2 1b1 2e1 2b10 2d9 3a11 
Phenobarbital 0.07 
c
± 0.04 0.75 ± 0.1 0.2 ± 0.09 1 ± 0.2 3.2 ± 0.7 2.5 ± 0.4 1.6 ± 0.1 
β-naphthoflavone 450 ± 330 30 ± 9 28 ± 8 1.1 ± 0.05 1.6 ± 0.2 2.4 ± 0.5 1.2 ± 0.3 
3-methylcholanthrene 11000 ±2900 180 ± 17 680 ± 120 1.5 ± 0.1 2.4 ± 0.7 2.9 ± 0.4 1.5 ± 0.4 
Dexamethasone 24 ± 16 4 ± 2 3.1 ± 1.7 0.78 ± 0.02 1.7 ± 0.2 18 ± 3.9 3.6 ± 1.0 
Aroclor 1254 7800 ± 2900 200 ± 39 370 ± 89 0.4 ± 0.1 8.4 ± 1.4 6.0 ± 1.4 5.5 ± 1.6 
FAA 1 treatment 0.003 ±0.001 0.08 ± 0.01 0.1 ± 0.01 0.6 ± 0.1 0.5 ± 0.08 0.5 ± 0.1 0.7 ± 0.1 
FAA 3 treatments 0.6 ± 0.3 1.9 ± 1.1 1.1 ± 0.3 2.1 ± 0.5 3.2 ± 1.5 2.3 ± 0.7 2.2 ± 0.4 
a
 Levels of Cyp transcripts were determined by quantitative RT-PCR as described in the Materials and 
Methods section.  
b 
The mouse Cyp orthologs correspondance with the human CYPs are as follows (mouse Cyp, human 
CYP): Cyp1a2, CYP1A2; Cyp1b1, CYP1B1; Cyp2b9, CYP2B6; Cyp2c39, CYP2C19; Cyp2d9, 
CYP2D6; Cyp2e1, CYP2E1; Cyp3a11, CYP3A4. 
c
 Fold-induction relative to their respective controls (saline or corn oil). Mean  ± SEM of 5 
independent determinations. 
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Legends for Figures 
 
Figure 1. A) Structure of flavone-8-acetic acid (FAA) and its phase I metabolites formed in 
vitro with mouse microsomes. B) Representative HPLC-UV chromatogram of FAA and its 
metabolites. 
 
Figure 2. HPLC-UV chromatogram showing FAA metabolism in absence (A), or presence of 
the Cyp1a2 inhibitor furafylline at a final concentration of 50 µg/ml (B). 
 
Figure 3. HPLC-UV chromatogram analysis (gradient elution) for the determination of direct 
or indirect hydroxylation using N-acetylcysteine (NAC), as an epoxide scavenger. A) 
chromatogram of FAA metabolism in absence of NAC. B) Chromatogram of FAA 
metabolism in presence of NAC at 7.5 mM. C) Reconstituted chromatogram at m/z = 460 of 
FAA metabolites in presence of NAC at 7.5 mM. D) Reconstituted chromatogram at m/z = 
460 of FAA metabolism in absence of NAC. 
 
Figure 4. HPLC-UV chromatograms depicting the involvement of epoxide hydrolase in the 
production of the 3',4'-dihydrodiol-FAA. A) FAA metabolism in absence of elaidamide, an 
epoxide hydrolase inhibitor. B) FAA metabolism in presence of elaidamide (10 µM). C) 
Histogram showing the elaidamide concentration dependent decrease in the formation of the 
3’,4’-dihydrodiol-FAA. 
 
Figure 5. Schematic summary of proposed FAA phase I metabolic pathways using aroclor-
induced mouse microsomes showing the principal enzymes involved. 
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